secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001829126-24-002415
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin CEO details clinical progress, Gen-3 HALO headset, and government market expansion
--------------------------------------------------------------------------------

- Positive clinical results from UCSD study: Gen-2 tACS reduced post-concussive and PTSD symptoms in veterans with mTBI.
- Published insomnia study showed statistically significant sleep improvements vs placebo; 6 additional peer-reviewed studies on 15mA waveform.
- New Gen-3 HALO Clarity headset with DIFS technology enables at-home treatment under Virtual Clinic remote physician monitoring; ahead of schedule.
- Formed military and government advisory board led by former Deputy Assistant Secretary of Defense; targeting DoD, VA, HHS markets.
- Received regulatory approval in Oman with sales to new Mental Health Center; patents extended through 2040 with four key patents and three pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624002415/0001829126-24-002415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624002415/nexalintechno_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-002415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer